MET and non-small cell lung carcinoma: The aberrant activation of MET signaling has been implicated in the development and progression of several malignancies, including non-small cell lung cancer (NSCLC) [2], gastric cancer [3,4], colorectal cancer [5], papillary renal cell carcinoma (PRCC) [6], hepatocellular carcinoma [7], and breast cancer [8,9].